Sinclair Pharma PLC Holding(s) in Company (5498L)
October 03 2016 - 9:56AM
UK Regulatory
TIDMSPH
RNS Number : 5498L
Sinclair Pharma PLC
03 October 2016
For filings with the FCA
include the annex
For filings with issuer exclude
the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
------------------------------------------------------------------------------------------------------
1. Identity of the issuer or Sinclair Pharma plc
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
--------------------------------------------------------------- -------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
------------------------------------------------------------------ ----------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------------ ----------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------------ ----------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------------ ----------------------------------
Other (please x
specify):
Change to
notifiable
interest following
share issue.
--------------------------------------------------------- ------- ----------------------------------
3. Full name of person(s) Abingworth LLP
subject to the Abingworth Bioventures V LP
notification obligation: Abingworth Bioequities Master
(iii) Fund Limited
----------------------------------------------------------- -----------------------------------------
4. Full name of shareholder(s) State Street (Nominees) Limited
(if different from 3.):(iv) (as nominee for Abingworth
Bioventures V LP)
Jefferies & Co Inc. (as nominee
for Abingworth Bioequities
Master Fund Limited)
----------------------------------------------------------- -----------------------------------------
5. Date of the transaction 30 September 2016
and date on
which the threshold is
crossed or
reached: (v)
----------------------------------------------------------- -----------------------------------------
6. Date on which issuer 3 October 2016
notified:
----------------------------------------------------------- -----------------------------------------
7. Threshold(s) that is/are Downward crossing of 6% threshold
crossed or - Abingworth LLP
reached: (vi, vii)
----------------------------------------------------------- -----------------------------------------
8. Notified details: Abingworth LLP
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
-------------- ---------------------------------- ------------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
-------------- ---------------- ---------------- -------------- ----------------------- -------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
-------------- ------------ ------------ -------------- --------- ------------ ------------ -----------
Sinclair
Pharma plc 33,433,227 29,674,270 5.91
GB0033856740
1p Ords
---------------- ---------------- -------------- --------- ------------ ------------ -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
(xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
------------------ -------------- -------------------------------- ------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
---------------- -------------- -------------- ---------------- ------------------------- -----------------------
Nominal Delta
---------------- -------------- -------------- ---------------- ------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
---------------------------------------------------- ----------------------------------------------------------------
29,674,270 5.91
---------------------------------------------------- ----------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
-----------------------------------------------------------------------------
Abingworth Bioventures V LP (which holds 22,573,542
shares in the company (4.50%)) and Abingworth Bioequities
Master Fund Limited (which holds 7,100,728 shares in
the company (1.41%)) are both managed by Abingworth
LLP.
Proxy Voting:
-----------------------------------------------------------------------------
10. Name of the proxy holder:
------------------------------------------------------------- --------------
11. Number of voting rights proxy
holder will cease
to hold:
------------------------------------------------------------- --------------
12. Date on which proxy holder will
cease to hold
voting rights:
------------------------------------------------------------- --------------
13. Additional information:
------------------------------------------------------------- --------------
14. Contact name: John Heard
------------------------------------------------------------- --------------
15. Contact telephone number: 0207 534 1500
------------------------------------------------------------- --------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLMJBITMBAMBAF
(END) Dow Jones Newswires
October 03, 2016 10:56 ET (14:56 GMT)
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From Apr 2024 to May 2024
Sinclair Pharma (LSE:SPH)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Sinclair Pha (London Stock Exchange): 0 recent articles
More Sinclair Pha News Articles